Emerging Nuplazid Litigation


NUPLAZID by Acadia Pharmaceuticals, Inc. (pimavanserin)












Nuplazid (pimavanserin) made by Acadia Pharmaceuticals Inc. was approved by the FDA in April of 2016 for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

Based on a review of the FDA adverse event reporting system,(FAERS) more than 5000 adverse events reports have been filed related to Nuplazid since its approval in 2016. Approximately 700 of these adverse event reports involved the death of the patient.

The FDA approved Nuplazid via the “Fast Track” process allowed for certain pharmaceutical products considered “break through therapies”

 Learn More About the Emerging Nuplazid Litigation

The emerging Nuplazid Litigation will be used as a case study in the May 18th to 21st 2018 Mass Tort Nexus, “Four Days to Mass Tort Success Course” to register for the May Course, contact Jenny Levine at or call (954) 520-4494.

For information on the class and to enroll- Enroll Here To Attend “Four Days to Mass Tort Success”



Course attendees will receive the benefit of a step by step analysis of the emerging Nuplazid Litigaton, using these primary metrics:

Mass Tort Nexus Metrics















See endorsements below of some of the top mass tort trial lawyers in the country who’ve attended the Mass Tort Nexus Immersion Course>


          DARIN SCHANKER, Bachus & Schanker, LLC  



            JERRY PARKER, Firm Founder, Parker Waichman, LLP


The Mass Tort Nexus Classes on Emerging Litigation and Ongoing Mass Torts is considered the premier source in the country to learn about the fundamentals of mass torts and how to enhance your firm practice, increase revenues and manage the related business operations effectively.  Don’t wait for the next class or next year, enroll today and learn what others already have, Mass Torts are where your firm can and will grow its practice.





Read More